Holen Sie sich die Stockscreener-App
96.84
0.24%
-0.11
Handel nachbörslich:
96.83
-0.01
-0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RVTY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$96.95
Offen:
$97.05
24-Stunden-Volumen:
2.19M
Relative Volume:
1.84
Marktkapitalisierung:
$10.80B
Einnahmen:
$2.90B
Nettoeinkommen (Verlust:
$239.11M
KGV:
45.87
EPS:
2.1112
Netto-Cashflow:
$492.45M
1W Leistung:
+0.89%
1M Leistung:
+11.47%
6M Leistung:
-7.59%
1J Leistung:
+8.27%
1-Tages-Spanne:
$95.34
$97.07
1-Wochen-Bereich:
$92.97
$97.07
52-Wochen-Spanne:
$81.22
$118.30
Revvity Inc Stock (RVTY) Company Profile
Firmenname
Revvity Inc
Sektor
Branche
Telefon
781-663-6900
Adresse
77 4TH AVENUE, WALTHAM
Compare RVTY vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
96.83 | 10.82B | 2.90B | 239.11M | 492.45M | 2.1112 |
TMO
Thermo Fisher Scientific Inc
|
448.27 | 166.59B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.86 | 121.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
557.15 | 44.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
338.72 | 33.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
115.09 | 32.49B | 7.07B | 1.29B | 993.00M | 4.5355 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-12-09 | Eingeleitet | Goldman | Neutral |
| 2025-10-16 | Eingeleitet | Guggenheim | Neutral |
| 2025-05-01 | Hochstufung | UBS | Neutral → Buy |
| 2025-01-10 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-07-08 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-23 | Fortgesetzt | Goldman | Buy |
Alle ansehen
Revvity Inc Aktie (RVTY) Neueste Nachrichten
Price-Driven Insight from (RVTY) for Rule-Based Strategy - Stock Traders Daily
Revvity stock (US76155R1086): life-science player after recent earnings in focus - AD HOC NEWS
Revvity, Inc. (RVTY) Stock Analysis: A Blend of Healthcare Innovation and Notable Growth Potential - DirectorsTalk Interviews
Revvity stock: Analyst estimates & ratings - MSN
Revvity stock (US76155R1086): cancer test launch and steady demand keep diagnostics group in focus - AD HOC NEWS
Revvity declares $0.07 dividend - MSN
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity Stock: Analyst Estimates & Ratings - inkl
Revvity stock (US76155R1086): diagnostics specialist in focus after latest earnings and life-science - AD HOC NEWS
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Revvity Inc. stock (US76155R1086): investors weigh latest earnings and diagnostics focus - AD HOC NEWS
There May Be Some Bright Spots In Revvity's (NYSE:RVTY) Earnings - 富途牛牛
Revvity's (NYSE:RVTY) Conservative Accounting Might Explain Soft Earnings - Yahoo Finance
Revvity stock (US76155R1086): Q1 earnings beat and guidance set the tone - AD HOC NEWS
Revvity (RVTY) Is Down 5.0% After Raising 2026 Outlook And Securing FDA Assay Clearance - Sahm
Revvity stock (US76155R1086): FDA assay clearance, outlook to 2026 and fresh collaboration momentum - AD HOC NEWS
Can Revvity Expand Diagnostics Across the S&P 500 Index? - Kalkine Media
Revvity, Inc. (RVTY): Investor Outlook Reveals 20.94% Potential Upside In Healthcare Innovation - DirectorsTalk Interviews
Revvity stock (US76155R1086): steady diagnostics player after latest quarterly update - AD HOC NEWS
RVTY expands endocrine diagnostics with FDA-cleared testosterone assay - MSN
Revvity stock (US76155R1086): collaboration momentum and diagnostics focus after recent share move - AD HOC NEWS
Revvity Inc. stock underperforms Friday when compared to competitors - MarketWatch
Revvity stock (US76155R1086): T. Rowe Price reports a 9% stake - AD HOC NEWS
FDA OKs Revvity’s Total Testosterone Assay - Medical Product Outsourcing
T. Rowe Price (RVTY) discloses 10.1M-share, 9.0% stake in Revvity - Stock Titan
(RVTY) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
The Top 5 Analyst Questions From Revvity’s Q1 Earnings Call - Yahoo Finance
Analysts Conflicted on These Healthcare Names: Cullinan Management (CGEM), Humacyte (HUMA) and Revvity (RVTY) - The Globe and Mail
Revvity stock (US76155R1086): Q1 earnings beat with $1.06 EPS - AD HOC NEWS
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay - The Globe and Mail
BofA Securities Maintains Revvity(RVTY.US) With Hold Rating - Moomoo
Is Revvity stock underperforming the S&P 500? - MSN
Is Revvity Inc (RVTY) a Bargain After 4.3% Drop? GF Value Says U - GuruFocus
Is Revvity Inc (RVTY) a Bargain After 4.3% Drop? GF Value Says Undervalued - GuruFocus
Revvity stock (US76155R1086): FDA clearance for testosterone assay, Q1 earnings beat - AD HOC NEWS
Transcript : Revvity, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 09 - marketscreener.com
FDA Clears Revvity Total Testosterone Assay for Automated Testing - Clinical Lab Products
Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution - Yahoo Finance
Revvity (RVTY) grows Q1 2026 sales to $711M while margins tighten - Stock Titan
Revvity stock (US76155R1086): Q1 earnings beat and analyst upgrade drive gains - AD HOC NEWS
Revvity (NYSE:RVTY) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Revvity Inc. stock outperforms competitors despite losses on the day - MarketWatch
Revvity (RVTY) director Alexis Michas receives stock awards and reports indirect holdings - Stock Titan
REVVITY (RVTY) director granted new restricted stock unit awards - Stock Titan
Revvity (RVTY) director Michael Klobuchar receives new restricted stock unit grants - Stock Titan
Revvity (RVTY) director Frank Witney granted restricted stock unit awards - Stock Titan
Director Samuel R. Chapin receives stock awards at REVVITY (RVTY) with RSUs vesting in 2027 - Stock Titan
Revvity (RVTY) director Michel Vounatsos receives new restricted stock units - Stock Titan
Revvity (RVTY) director Michelle McMurry-Heath granted new RSU awards - Stock Titan
Equity grants add 2,280 shares to Revvity (RVTY) director’s stake - Stock Titan
Revvity (RVTY) Q1 2026 Earnings Transcript - AOL.com
Finanzdaten der Revvity Inc-Aktie (RVTY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.43%
0.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):